This study investigates the demographic and clinical features of conjunctival tumours. Conjunctival tumours include a large spectrum of conditions ranging from benign lesions to aggressive, life-threatening malignancies. Knowing the distribution of conjunctival tumours by age and gender is important for reducing cancer morbidity. The clinical records of 375 patients (410 eyes) diagnosed with a conjunctival mass at a tertiary referral centre between February 1999 and November 2020 were retrospectively evaluated. Two-hundred-seventeen (57.9%) patients were male and 158 (42.1%) were female. Of 410 conjunctival tumours, 159 (38.8%) were benign, 106 (25.9%) premalignant, and 145 (35.4%) malignant. Overall, the 3 most common diagnoses were squamous cell carcinoma (SCC, 19.5%), conjunctival intraepithelial neoplasia (CIN, 18.3%), and naevus (17.8%). The most common benign, premalignant, and malignant tumours were naevus (n = 73/159, 45.9%), CIN (n = 75/106, 70.8%), and SCC (n = 80/145, 55.2%) respectively. Naevus was the most common tumour in ≤20 years and > 20-40 years old patient groups (56.2% and 25.4% respectively). CIN was the most frequent tumour in patients aged > 40-60 years (25.7%). SCC was the most common tumour in > 60-80 years and > 80 years old patient groups (44.3% and 80.0% respectively). The median patient age was greater in patients with malignant tumours (64.5 years) compared to patients with premalignant (55.5 years, p = 0.011) and benign tumours (22.0 years, p < 0.001). Malignant tumours displayed larger base diameter, greater thickness, and intrinsic vessels compared to premalignant or benign lesions (p < 0.001 for each parameter). Malignant tumours also displayed more amelanotic vs melanotic appearance (p < 0.001) and limbal vs extralimbal bulbar location compared to benign lesions (p < 0.001). Premalignant and malignant tumours comprised 61.2% of all conjunctival tumours and were usually detected in patients > 40 years of age in this study.
Background Allergic rhinitis (AR) is a common allergic diseases which affect a patient’s quality of life. Another important disease which has a negative impact on quality of life is fibromyalgia (FM). Some studies have suggested that a probable relationship exists between atopic diseases and FM. Objectives This study was designed to determine the prevalence of FM and its impact on quality of life among AR patients. Methods One hundred five consecutive adult patients with AR who were between 18 and 57 years old were prospectively recruited in this study between April 2017 and May 2018. All patients were evaluated for the presences of FM. Patients were diagnosed with FM according to the classification criteria of the 2010 American College of Rheumatology. The patients’ quality of life was evaluated by Turkish versions of the Rhinoconjunctivitis Quality of Life Questionnaire and the Nottingham Health Profile (NHP). Results Thirty-four patients were diagnosed as having FM (32.4%). The percentage of FM was considerably higher than in the general population (2%–5%). Median individual domain scores except practical problems ( P = .108) and eyes symptoms ( P = .227) were significantly higher in AR with FM patients ( P < .001). All median levels of the NHP domains were significantly higher in AR with FM patients ( P < .001). Conclusion We would like to suggest that FM may be considered as one of the overlooked comorbid conditions in AR patients. Physicians should be aware of the occurrence of FM, especially in patients with impaired quality of life.
ABS TRACT Objective:To correlate high-resolution computed tomography (HRCT) imaging findings of chronic otitis media (COM) with and without cholesteatoma regarding the presence, site, and severity of bone defects.Material and Methods: Temporal bone HRCT images of patients with COM, obtained between 2011 and 2022, were retrospectively reviewed.Patients with a soft tissue mass in the tympanic cavity were allocated into either COM with cholesteatoma (CH+COM) or without cholesteatoma group (CH-COM) based on pathology results and-/or magnetic resonance imaging findings.Computed tomography images were analyzed with regard to the presence, site, and severity of middle ear bone erosions/defects and group comparisons were made.Results: A total of 60 patients (CH+COM: 23 patients, CH-COM: 37 patients) were included.Blunting of the scutum, defect of the tegmen tympani, absence/incompleteness of the Körner's septum, erosion of the ossicular chain, and destruction of the medial and lateral tympanic walls were significantly more frequent in the CH+COM group (p<0.05).While small bone discontinuities (≤2 mm) of the tegmen tympani or blunting of the scutum were present in both groups, a greater defect of these structures was observed only in the CH+COM group.No significant difference was detected neither regarding the location of the soft tissue masses nor the presence of posterior wall defects (p>0.05).Conclusion: Radiologists should be aware of bone erosions when evaluating temporal bone HRCT images of patients with COM, even if cholesteatoma is not suspected.Furthermore, reporting the severity of bone destruction could be a helpful hint regarding the presence of cholesteatoma and might impact surgical planning.
ÖzAmaç: Duraplasti, yara yerinin optimal düzeyde iyileşmesi ve olası komplikasyonların önlenmesi adına oldukça önemlidir.Bu çalışmada, duraplastiye yönelik tarafımızca geliştirilen "katlantı tekniğinin" ameliyat sırasında kullanımına dair teknik nüanslara ve söz konusu tekniğin, primer duraplasti-
To evaluate the risk factors leading to recurrence and new tumor (NT) development in patients with retinoblastoma after intravenous chemotherapy (IVC) and to review the treatment outcomes.The records of 166 retinoblastoma cases (having 246 affected eyes) who underwent six-cycle IVC (vincristine, etoposide, and carboplatin) as primary treatment between October 1999 and August 2020 were reviewed retrospectively.The mean ages at presentation were 9.0 (median: 8.0) and 9.2 (median: 8.5) months in cases with recurrence and NTs respectively. Recurrence was detected in 40 (16.3%) eyes, NTs in 29 (11.8%), and both recurrence/NTs in 24 (9.8%). The mean time elapsed till recurrence and NT was 10.7 months. Multivariable analysis showed that the factors predictive of recurrence were largest tumor base diameter (LTBD) >12 mm (p = 0.039) and presence of subretinal seeds at diagnosis (p = 0.043). Multivariable risk factors for the development of NTs were bilateral familial retinoblastoma (p = 0.001) and presence of subretinal seeds at diagnosis (p = 0.010). Mean follow-up was 80.1 (median: 72.5) months. By Kaplan-Meier analysis, the 1-, 3-, and 6-year recurrence and NT rates were 21.2%, 28.1%, and 28.7% and 14.9%, 22.6%, and 23.9% respectively. The most common treatment methods used for recurrent and/or NTs included cryotherapy, transpupillary thermotherapy, and intra-arterial chemotherapy. Enucleation was eventually required in 24/93 (25.8%) eyes. No patient developed metastasis.Development of recurrence and/or NT after IVC was noted in 38% of all retinoblastoma eyes. Bilateral familial disease, LTBD >12 mm, and presence of subretinal seeds at baseline were risk factors for recurrence and NTs in this study.